Delving into the Latest Updates on Ustekinumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-interleukin-12 p40 monoclonal antibody, Stellara, Sterrara

+ [13]

Target

IL-12 x IL-23

Action

inhibitors

Mechanism

IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [4]

Active Indication

Colitis, UlcerativeCrohn DiseaseArthritis, Psoriatic+ [11]

Inactive Indication

Colitis, MicroscopicDermatomyositisHand-Foot Syndrome+ [18]

Originator Organization

Janssen Biotech, Inc.

Active Organization

Janssen Research & Development LLCJanssen-Cilag International NVJanssen Scientific Affairs LLC

+ [7]

Inactive Organization

Centocor, Inc.Janssen Ortho LLCJanssen-Cilag Ltd.

+ [4]

License Organization

Janssen Pharmaceuticals, Inc.

Mitsubishi Tanabe Pharma Corp.

Drug Highest PhaseApproved

First Approval Date

European Union (15 Jan 2009),

Arthritis, PsoriaticCrohn's disease, active moderateCrohn's disease, active severe+ [3]

RegulationOrphan Drug (United States), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Login to view timeline

Structure/Sequence

Sequence Code 143665H

Source: *****

Sequence Code 143874L

Source: *****

the goal of this study is to compare the efficacy of ustekinumab with infliximab for the treatment of ulcerative colitis aim of the study :
1. Compare effectiveness of ustekinumab versus infliximab therapy in remission achievement in UC patients.
2. Compare safety of ustekinumab therapy versus infliximab therapy in UC
3. To asses quality of life of ustekinumab therapy versus infliximab therapy in UC patients.

Start Date15 May 2025

Sponsor / Collaborator

Helwan University

NCT06788340

/ Not yet recruitingPhase 4IIT

MOdel-Informed Precision Dosing (MIPD) of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - an Independent Randomized Controlled Trial

The goal of this clinical trial is to investigate if dosage of Ustekinumab (UST) and Vedolizumab (VDZ) based on Model-Informed Precision Dosing (MIPD) is equally as efficient in keeping adults with Inflammatory Bowel Disease (IBD) in remission as management based on what the treating physician deems best. The main question is:
Is using pharmacokinetic-pharmacodynamic (PK-PD) models to predict the appropriate dose and dosing interval for VDZ and UST at least as effective as current practices in maintaining IBD remission.
As above mentioned the comparison-group is adults with IBD, treated with UST or VDZ, managed as the physician deems best.
Participants will:
Have blood and stool tests done, as well as answer a questionnaire 4th weekly Have their dosage frequency decided on either by the PK-model or as the physician deems best visit the clinic once every 24 weeks for checkups. Have an endoscopy done at completion of the study (if the disease is primarily located in the small intestine, MRI or capsule endoscopy will be used instead)

Start Date01 May 2025

Sponsor / Collaborator

Odense University Hospital

100 Clinical Results associated with Ustekinumab

Login to view more data

100 Translational Medicine associated with Ustekinumab

Login to view more data

100 Patents (Medical) associated with Ustekinumab

Login to view more data

3,419

Literatures (Medical) associated with Ustekinumab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective

Article

Author: Upadhyay, Navneet ; Creveling, Thomas ; Fisher, Deborah A. ; Mittal, Neha ; Chanan, Neha ; Bires, Nicholas ; Kane, Sunanda ; Gulati, Ankit ; Koushik, Amit Kumar

INTRODUCTION:

Mirikizumab, approved for the treatment of moderately to severely active ulcerative colitis (UC), may be prescribed in a similar placement to ustekinumab in second-line settings. Payers may compare the economic value when making formulary decisions. This study estimated and compared the cost per remission of the second-line therapies mirikizumab versus ustekinumab in patients with UC.

METHODS:

An Excel-based analytic model was developed to estimate the cost per additional patient achieving clinical remission at the end of one year in biologic/Janus kinase inhibitor (JAKi)-experienced patients (second-line therapy) with UC from a United States commercial payer perspective. A network meta-analysis of published pivotal randomized clinical trials was used to derive the number needed to treat (NNT) for clinical response, clinical remission, and endoscopic remission/endoscopic improvement/mucosal healing for ustekinumab and mirikizumab in the study population. The model included the treatment cost (wholesale acquisition costs [WAC] and treatment administration costs) during the induction and maintenance phases. A scenario involving the availability of a ustekinumab biosimilar was also evaluated, assuming the NNT remained the same as ustekinumab but with a WAC set at 50% lower than its current WAC.

RESULTS:

The costs per patient achieving clinical remission for mirikizumab vs. ustekinumab as a second-line therapy were $461,096 vs. $67,273 during induction and $501,456 vs. $1,079,189 during maintenance. The cost per clinical remission in case of dose escalation during maintenance was lower for mirikizumab vs. ustekinumab ($501,456 vs. $1,569,127). Considering the ustekinumab 130 mg IV biosimilar, the scenario resulted in a lower cost per clinical remission for mirikizumab vs. a ustekinumab biosimilar during the maintenance phase ($501,456 vs. $539,594).

CONCLUSION:

Mirikizumab is projected to have a lower cost per remission during maintenance therapy than ustekinumab. Given the need for long-term treatment for this chronic condition, mirikizumab appears to be a cost-efficient treatment option.

01 Dec 2025·Current gastroenterology reports

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations

Review

Author: Jennings, William ; Fudman, David ; Rotondo-Trivette, Sarah

PURPOSE OF REVIEW:

This review summarizes the literature on IL-23 inhibitors for inflammatory bowel disease and the role of these agents in clinical practice.

RECENT FINDINGS:

The last decade has seen several pivotal trials investigating IL-23 inhibitors. These agents are effective in inducing and maintaining remission of moderate-to-severe inflammatory bowel disease, including among those with prior biologic failure, and have low adverse events. IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences.

01 Dec 2025·IMMUNOLOGIC RESEARCH

A patient with CVID-enteropathy successfully treated with ustekinumab

Article

Author: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark

CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.

487

News (Medical) associated with Ustekinumab

20 Jun 2025

·www.prnewswire.com

Bio-Thera Solutions Receives Positive CHMP Opinion for USYMRO®(ustekinumab), a Biosimilar Referencing Stelara®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO® to the reference product Stelara® GUANGZHOU, China, June 20, 2025 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for USYMRO® (ustekinumab), a biosimilar monoclonal antibody referencing Stelara®. The CHMP's positive opinion will now be referred to the European Commission, which will decide whether to grant marketing authorization for USYMRO®. "Bio-Thera is committed to being one of the premier biosimilar developers and manufacturers in the world," said Shengfeng Li, CEO of Bio-Thera Solutions. "The positive CHMP recommendation for USYMRO® builds on Bio-Thera's track record of accomplishment as a biosimilar developer and manufacturer." This positive CHMP opinion on USYMRO® was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. Extensive analytical characterization of the structural, physicochemical, and biological properties of USYMRO® was conducted and supports biosimilarity with the reference biologic product. Additionally, a randomized double-blind, single-dose, three-arm, parallel group Phase 1 study compared the pharmacokinetics, safety and immunogenicity of USYMRO® with both the EU and US reference product in healthy volunteers. In addition, a randomized, double-blind, multi-dose, three-arm, parallel group Phase 3 study compared USYMRO® with the reference product to confirm equivalent efficacy and comparable pharmacokinetic, safety and immunogenicity profiles, in subjects with severe plaque psoraisis. The totality of evidence demonstrated USYMRO® is a biosimilar of the reference biologic. Bio-Thera and Gedeon Richter entered into a license and commercialization agreement for USYMRO® (BAT2206) in October of 2024. Under the terms of the agreement, Bio-Thera is responsible for the development and manufacturing of the product. Gedeon Richter will have the right to commercialize the medicine upon approval and successful Marketing Authorization Holder Transfer in the EU, the UK and Switzerland. About USYMRO® (ustekinumab) USYMRO® is a biosimilar to Janssen's Stelara® which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 subunit from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of immune cells. IL-12 and IL-23 are involved in inflammatory and immune responses, such as natural killer cell activation, CD4+ T-cell differentiation and following relative cytokines stimulated release. Abnormal regulation of IL-12 and IL-23 have been implicated as important contributors to chronic inflammation, including psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), and Ulcerative colitis (UC). Neutralizing human IL-12 and IL-23 by USYMRO® to prevent the relevant cell signaling in the Th1 or Th17 lineages can effectively block the pathologic processes of these immune disorders. About Bio-Thera Solutions Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including five approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® in the US, and BAT1806/TOFIDENCETM (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and in EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit or follow us on X (@bio_thera_sol) and WeChat (Bio-Thera). Cautionary Note Regarding Forward-Looking Statements This news release contains certain forward-looking statements relating to USYMRO® / BAT2206 or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing "could," "may," "should," "will," "would," "anticipate," "believe," "plan," "promising," "potentially," or similar expressions. They reflect the company's current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies, for example, the development processes could be lengthy and high in vitro affinity may not translate to desired results in vivo or successful clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company's financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company's views or otherwise. USYMRO® is a registered trademark of Gedeon Richter Plc STELARA® is a registered trademark of Johnson and Johnson QLETLI® is a registered trademark of Bio-Thera Solutions, Ltd. BETAGRIN® is a registered trademark of Bio-Thera Solutions, Ltd. STARJEMZA® is a registered trademark of Hikma Pharmaceuticals. TOFIDENCE™ is a trademark of Organon LLC AVZIVI® is a registered trademark of Sandoz POBEVCY® is a registered trademark of Bio-Thera Solutions, Ltd. Bio-Thera Contacts Bio-Thera Solutions, Ltd.: Bert E. Thomas IV +1.410.627.1734 [email protected] SOURCE Bio-Thera Solutions, Ltd WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inPhase 3Drug ApprovalClinical ResultPhase 1

17 Jun 2025

·www.pharmaceutical-technology.com

Teva to collaborate with Fosun Pharma for TEV-56278

TEV-56278 has been specifically engineered to target PD-1 + T cells selectively. Credit: alicancomertpay/Shutterstock. Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed cell death protein 1 (PD1)-Interleukin-2 (IL2) ATTENUKINE therapy, TEV-56278. The collaboration will enhance clinical data generation for the potential treatment, which utilises Teva’s ATTENUKINE technology designed to offer efficacy with low toxicity across various oncology indications. Teva Global research and development (R&D) executive vice-president and chief medical officer Eric Hughes stated: “This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring the acceleration of our pipeline. “TEV-56278 demonstrates the strength of Teva’s innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.” Fosun Pharma will have exclusive rights to develop, manufacture and commercialise the therapy in Mainland China, the Hong Kong Special Administrative Region (SAR), Macau SAR, the Taiwan region and selected countries in Southeast Asia. Teva retains all corresponding rights outside of these territories. The deal provides the company with insights from Fosun Pharma’s regional data that can be leveraged globally. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Fosun Pharma executive president and global R&D centre CEO Xingli WANG stated: “We are pleased to partner with Teva on the development of TEV-56278. “This collaboration brings together Teva’s expertise in innovative drug development with Fosun Pharma’s strong oncology development experience and commercial capabilities in the China market, creating a powerful synergy to accelerate the delivery of this important therapy to patients globally.” TEV-56278 has been specifically engineered to target PD-1 + T cells selectively. This targeted method could significantly improve patient outcomes across multiple oncology diseases. In February 2025, Teva and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

License out/in

17 Jun 2025

·pmlive.com

FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

The US Food and Drug Administration (FDA) has approved a new presentation of Celltrion’s SteQeyma, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat paediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA). The drug is now authorised as a 45mg/0.5ml solution in a single-dose vial for subcutaneous injection in patients aged six to 17 years who weigh less than 60kg. It is hoped that the approval, which means that SteQeyma now offers all dosage forms and strengths of its reference product, will help meet physicians’ clinical needs and support treatment continuity for patients. Approximately 125 million people worldwide are affected by some form of psoriasis, a chronic inflammatory condition that typically affects the skin, nails and joints. PsO occurs in up to 90% of psoriasis patients and is characterised by distinct round or oval plaques that are usually covered by silvery-white scales. PsA, which causes joint pain, swelling and stiffness, is less common, affecting around 30% of psoriasis patients. The FDA’s decision comes six months after it approved SteQeyma 45mg/0.5ml and 90mg/ml in a single-dose prefilled syringe for subcutaneous injection, and SteQeyma 130mg/26ml in a single-dose vial for intravenous infusion. The December authorisation applied to adult and paediatric patients aged six years and older with PsO and PsA, as well as adults with Crohn’s disease and ulcerative colitis. Among the evidence supporting the regulator’s latest approval of SteQeyma were positive results from a phase 3 study in adults with moderate-to-severe PsO, in which Celltrion’s biosimilar and Stelara showed no clinically meaningful differences in terms of safety and efficacy. Hetal Patel, vice president of medical affairs at Celltrion USA, said: “Managing inflammatory diseases in paediatric patients can be particularly complex. “The new dosage form and strength of SteQeyma allow us to better meet the specific needs of young patients, giving physicians a valuable treatment option with flexibility, supported by a well-established safety and efficacy profile.” Celltrion outlined that the FDA has also granted SteQeyma full interchangeability across all indications of Stelara, “following the expiration of exclusivity for the first interchangeable biosimilar on 30 April 2025”.

Clinical ResultPhase 3Drug Approval

100 Deals associated with Ustekinumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09214	Ustekinumab	L04AC05	DB05679

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Colitis, Ulcerative	Australia	Janssen-Cilag Pty Ltd.	28 Jul 2009
Crohn Disease	Australia	Janssen-Cilag Pty Ltd.	28 Jul 2009
Arthritis, Psoriatic	European Union	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	Iceland	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	Liechtenstein	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	Norway	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	European Union	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	Iceland	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	Liechtenstein	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	Norway	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	European Union	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	Iceland	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	Liechtenstein	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	Norway	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	European Union	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	Iceland	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	Liechtenstein	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	Norway	Janssen-Cilag International NV	15 Jan 2009
Ulcerative colitis, active moderate	European Union	Janssen-Cilag International NV	15 Jan 2009
Ulcerative colitis, active moderate	Iceland	Janssen-Cilag International NV	15 Jan 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	Phase 3	United States	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Argentina	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Denmark	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	France	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Germany	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Italy	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Poland	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Spain	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	Turkey	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	United Kingdom	Janssen Research & Development LLC	30 Aug 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04882072 (Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis, Pubmed \| Rheumatol Adv Pract)	Phase 3	Takayasu Arteritis	14	Ustekinumab	yeuyfixmep(xceqgxcbci) = ypwvblircz mfgycqspru (xqqollxwdg, 4.14 - NE)	Negative	14 Mar 2025
				Placebo	yeuyfixmep(xceqgxcbci) = fhhkvvidkf mfgycqspru (xqqollxwdg, 12.14 - NE)
NCT04549792 (CTgov)	Early Phase 1	Sjogren-Larsson Syndrome \| Ichthyosis	13	Ustekinumab	thccezmxmz(nsoziazsrg) = gvexxochru jkbyhmhsfr (nmzcqccrts, 29.9) View more	-	12 Feb 2025
NCT04882072 (Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritis, CTgov)	Phase 3	Takayasu Arteritis	14	placebo+ustekinumab (Double-blind: Placebo)	yqfvpuavhv(lizuhtbuak) = myhjfzfsgr lalkqllkyx (grroxgcptu, bphmlqjswe - vwxhriowqw) View more	-	02 Dec 2024
				Ustekinumab (Double-blind: Ustekinumab)	yqfvpuavhv(lizuhtbuak) = nlrqoxyspo lalkqllkyx (grroxgcptu, cadjezqypi - argxsmwnkt) View more
NCT04629196 (CTgov)	Phase 4	Crohn Disease	12	Ustekinumab (IV Weight-Based Induction Dose)	sfpylwfsbm(gklcjwwbmk) = bgirbmufmj yvdqhqxbdq (wkdediekmp, 64.82) View more	-	05 Nov 2024
				Ustekinumab (Standard Subcutaenous Dose)	sfpylwfsbm(gklcjwwbmk) = flzmngoxlr yvdqhqxbdq (wkdediekmp, 47.14) View more
UEGW2024	Not Applicable	-	-	Cohort 1	qvkaufwrom(peesetrplo) = kewpgisalj cjhoyjzzqg (sylwqxvhux ) View more	-	13 Oct 2024
				Cohort 2	qvkaufwrom(peesetrplo) = yvrnehmeph cjhoyjzzqg (sylwqxvhux )
UEGW2024	Not Applicable	Inflammatory Bowel Diseases	-	Intravenous Ustekinumab 130mg/4 weeks	nzuxrgzbnr(koqexrkopy) = 2 patients (both with CD) experienced recurrent respiratory infections as an adverse effect, without the need to discontinue UST xjtvcjvlet (qrjtrrllru )	-	13 Oct 2024
UEGW2024	Not Applicable	Colitis, Ulcerative	-	Ustekinumab 90 mg every-8-weeks	dolxlvlnvf(tjesnxvwzw) = A total of 176 patients (28%) had at least one adverse event, with infections being the most frequent (11%). No negative impact on extraintestinal manifestations and/or immunomediated diseases was seen. yusxkmbnzt (cuoqxzbkbe )	-	13 Oct 2024
UEGW2024	Not Applicable	Colitis, Ulcerative	-	Ustekinumab	lmzxjgsiof(bqeinzrpyn) = 62 adverse drug reactions were recorded in 36 patients tcikipgtpb (kflqzdvkip ) View more	-	13 Oct 2024
UEGW2024	Not Applicable	-	17	Ustekinumab	niljrxpqud(kjmgupwdwa) = knhwamsndv fstoqzturw (uvqthjccqg )	Positive	13 Oct 2024
UEGW2024	Not Applicable	Colitis, Ulcerative	-	Ustekinumab	dbvdombpjg(kczxollbxv) = Adverse events were reported in 14.1% (18/198), with colectomies exclusively observed in bio-exposed individuals (8.6%; 17/198) hxvsgbjotf (trnrlqilve )	-	13 Oct 2024
				Ustekinumab (Bio-naive patients)

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Ustekinumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation